RESEARCHERS FIND LOW COST DRUG WIPES OUT DRUG RESISTANT TB, BUT WORRY IT MAY NOT REACH PATIENTS IN NEED An off-patent anti-inflammatory drug that costs around two cents for a daily dose in developing countries

Could reduce treatment by more than a year for some patients A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found